Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
DASATINIB DR.REDDY'S, DASATINIB-DRLA, DASATINIB-RZ, REDDY'S-DASATINIB (Dr Reddys Laboratories Australia Pty Ltd)
Product name
DASATINIB DR.REDDY'S, DASATINIB-DRLA, DASATINIB-RZ, REDDY'S-DASATINIB
Date registered
Evaluation commenced
Decision date
Approval time
151 (255 working days)
Active ingredients
dasatinib propylene glycol
Registration type
New generic medicine
Indication
DASATINIB DR.REDDY'S, DASATINIB-DRLA, DASATINIB-RZ, REDDY'S-DASATINIB (tablet) is indicated for the treatment of adults aged 18 years or over with:
- newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.
- Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.
DASATINIB DR.REDDY'S, DASATINIB-DRLA, DASATINIB-RZ, REDDY'S-DASATINIB is indicated for the treatment of paediatric patients with:
- newly diagnosed Ph+ ALL in combination with chemotherapy.